Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001493152-22-033192
Filing Date
2022-11-21
Accepted
2022-11-21 19:15:32
Documents
1
Period of Report
2020-08-01

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 2977
  Complete submission text file 0001493152-22-033192.txt   4406
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Issuer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 680 E COLORADO BLVD. SUITE 180 PASADENA CA 91101
Business Address
Miser James (Reporting) CIK: 0001857596 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39717 | Film No.: 221407104